Aliabbas A. Husain

Aliabbas A. Husain

Auto-generated profile, based on publicly available information

Aliabbas A. Husain

Advanced Research Center, Central India Institute of Medical Sciences, Bajaj Nagar, Nagpur, Maharashtra, India

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 April 2021 in Epidemiology and Health
Verified
Journal Article
Open access
PDF file
AHAliabbas A. Husain
Aliabbas A. Husain
AKAndreas Kupz
Andreas Kupz
RKRajpal Singh Kashyap
Rajpal Singh Kashyap
India has a higher tuberculosis (TB) burden than any other country, accounting for an estimated one-fourth of the global burden. Drug-resistant tuberculosis (DR-TB) presents a major public health problem in India. Patients with DR-TB often require profound changes in their drug regimens, which are invariably linked to poor treatment adherence and sub-optimal treatment outcomes compared to drug-sensitive TB. The challenge of addressing DR-TB is critical for India, as India contributes over 27% of global DR-TB cases. In recent decades, India has been proactive in its battle against TB, even implementing a revised National Strategic Plan to eliminate TB by 2025. However, to achieve this ambitious goal, the country will need to take a multifaceted approach with respect to its management of DR-TB. Despite concerted efforts made by the National TB Elimination Program, India faces substantial challenges with regard to DR-TB care, especially in peripheral and resource-limited endemic zones. This article describes some of the major challenges associated with mitigating the growing DR-TB epidemic in India and their implications.

1 May 2023 in The Lancet Regional Health - Southeast Asia
Verified
Journal Article
Open access
SSStephen Stockdale
Stephen Stockdale
ABAdam Blanchard
Adam Blanchard
ANAmit Nayak
Amit Nayak
AHAliabbas Husain
Aliabbas Husain
RNRupam Nashine
Rupam Nashine
TMTanya M. Monaghan
Tanya M. Monaghan
The COVID-19 pandemic showcased the power of genomic sequencing to tackle the emergence and spread of infectious diseases. However, metagenomic sequencing of total microbial RNAs in wastewater has the potential to assess multiple infectious diseases simultaneously and has yet to be explored. A retrospective RNA-Seq epidemiological survey of 140 untreated composite wastewater samples was performed across urban (n = 112) and rural (n = 28) areas of Nagpur, Central India. Composite wastewater samples were prepared by pooling 422 individual grab samples collected prospectively from sewer lines of urban municipality zones and open drains of rural areas from 3rd February to 3rd April 2021, during the second COVID-19 wave in India. Samples were pre-processed and total RNA was extracted prior to genomic sequencing. This is the first study that has utilised culture and/or probe-independent unbiased RNA-Seq to examine Indian wastewater samples. Our findings reveal the detection of zoonotic viruses including chikungunya, Jingmen tick and rabies viruses, which have not previously been reported in wastewater. SARS-CoV-2 was detectable in 83 locations (59%), with stark abundance variations observed between sampling sites. Hepatitis C virus was the most frequently detected infectious virus, identified in 113 locations and co-occurring 77 times with SARS-CoV-2; and both were more abundantly detected in rural areas than urban zones. Concurrent identification of segmented virus genomic fragments of influenza A virus, norovirus, and rotavirus was observed. Geographical differences were also observed for astrovirus, saffold virus, husavirus, and aichi virus that were more prevalent in urban samples, while the zoonotic viruses chikungunya and rabies, were more abundant in rural environments. RNA-Seq can effectively detect multiple infectious diseases simultaneously, facilitating geographical and epidemiological surveys of endemic viruses that could help direct healthcare interventions against emergent and pre-existent infectious diseases as well as cost-effectively and qualitatively characterising the health status of the population over time. 10.13039/100014013 UK Research and Innovation (UKRI) 10.13039/100016270 Global Challenges Research Fund (GCRF) grant number H54810, as supported by Research England.

1 January 2015 in Clinical and Experimental Vaccine Research
Verified
Journal Article
Open access
PDF file
AHAliabbas A. Husain
Aliabbas A. Husain
SWShubhangi R. Warke
Shubhangi R. Warke
DKDewanand R. Kalorey
Dewanand R. Kalorey
HDHatim F. Daginawala
Hatim F. Daginawala
GTGirdhar M. Taori
Girdhar M. Taori
RKRajpal S. Kashyap
Rajpal S. Kashyap
Husain AA, et al. Clin Exp Vaccine Res. 2015 Jan;4(1):83-87. https://doi.org/10.7774/cevr.2015.4.1.83

1 January 2016 in Clinical and Experimental Vaccine Research
Verified
Journal Article
Open access
PDF file
AHAliabbas A. Husain
Aliabbas A. Husain
HDHatim F. Daginawla
Hatim F. Daginawla
LSLokendra Singh
Lokendra Singh
RKRajpal S. Kashyap
Rajpal S. Kashyap
Husain AA, et al. Clin Exp Vaccine Res. 2016 Jan;5(1):31-40. https://doi.org/10.7774/cevr.2016.5.1.31

16 September 2015 in International Journal of Peptide Research and Therapeutics
Verified
Journal Article
Open access
PDF file
AHAliabbas A. Husain
Aliabbas A. Husain
HDHatim F. Daginawala
Hatim F. Daginawala
SWShubhangi R. Warke
Shubhangi R. Warke
DKDewanand R. Kalorey
Dewanand R. Kalorey
NKNitin V. Kurkure
Nitin V. Kurkure
RKRajpal S. Kashyap
Rajpal S. Kashyap
Limited experimental evidences are available on the use of peptides as vaccines to boost BCG induced immunity for protection against tuberculosis. The present study therefore evaluated protective efficacy of booster dose of N-terminal peptides of Ag85B, using prime boost approaches in murine model of tuberculosis. Using earlier established subcutaneous murine model of TB in our laboratory, we compared the protective vaccination efficacy of peptides of Ag85B with that of booster dose of whole Ag85B and BCG by evaluating both antibody and cell-mediated immune response. Groups of mice primed by BCG and boosted with Ag85B peptides showed limited pulmonary bacillary burden and reduced lung pathology after challenge with virulent dose of Mycobacterium tuberculosis in mice. Significant levels (p < 0.001) of BCG specific antibodies (anti-BCG, anti-PPD) and T cell-specific cytokines were observed in Ag85B peptides boosted mice compared to Ag85B and BCG. Ag85B and BCG boosted mice however showed significant protection compared to single BCG dose and unvaccinated control groups. Our result suggests that prime boost strategy using N-terminal peptides of Ag85B may improve immunogenicity of BCG against TB. Such peptides may be attractive candidates for boosting waning BCG induced immune response in near future. However study demands further work including improvisation in experimental designs to justify the results.

24 January 2025 in Research Square
Verified
Preprint
Open access
PDF file
ANAmit R Nayak
Amit R Nayak
AHAliabbas Husain
Aliabbas Husain
JBJawad Baksh
Jawad Baksh
DKDewanand R. Kalorey
Dewanand R. Kalorey
NKNitin Kurkurey
Nitin Kurkurey
RKRajpal S Kashyap
Rajpal S Kashyap
This study aimed to develop a cost-effective middle cerebral artery occlusion (MCAO) model in rats using an intraluminal suture method with a magnifying glass lens, an alternative to a surgical microscope. Male Sprague-Dawley rats underwent MCAO surgery, and neurological deficits were assessed post-surgery. Neurological scores were significantly higher in MCAO rats (mean score 3.5 ± 0.5) compared to sham-operated controls (mean score 0.5 ± 0.2) (p < 0.001). 2,3,5-Triphenyltetrazolium chloride (TTC) staining revealed significant infarction in the ischemic region (mean infarct volume 45.2 ± 5.6%), while no infarct was observed in sham-operated controls (0%). Histopathological analysis confirmed ischemic damage, and immunofluorescence staining showed reduced NeuN (62.4% ± 8.2%) and GFAP (70.3% ± 7.5%) expression in the ischemic cortex compared to sham (p < 0.01). Brain water content was significantly higher in the ischemic hemisphere (82.5% ± 2.1%) compared to the contralateral hemisphere (78.4% ± 1.3%) (p < 0.05). The magnifying glass lens-based technique provided a reliable, cost-effective alternative for MCAO surgery, maintaining high reproducibility. This model can be used for preclinical stroke research, neuroprotective studies, and investigating ischemic pathophysiology, especially in resource-limited settings. Overall, the magnifying glass lens MCAO model proves to be an effective tool for stroke research and translational studies in low-resource environments.